Society of Cannabis Clinicians

Educating Healthcare Professionals
About the Medical Use of Cannabis

Who We Are

The SCC is a nonprofit educational and scientific society of healthcare professionals and allies dedicated to advancing research and disseminating knowledge about medical cannabis.

Physician Locator Map

Are you looking for a cannabis-knowledgable physician? Are you a healthcare provider wanting to highlight your practice? Our Locator Map guides prospective patients to clinician members.

Research Library

The SCC supports the practice of evidence-based cannabinoid medicine. All articles in the collection have been vetted to ensure only rigorous, unbiased, and non-commercialized studies are included.

COURSE OFFERINGS

Latest News

, , ,

Antiviral activities of hemp cannabinoids

Hemp is an understudied source of pharmacologically active compounds and many unique plant secondary metabolites including more than 100 cannabinoids. After years of legal restriction, research on hemp has recently demonstrated antiviral activities in silico, in vitro, and in vivo for cannabidiol (CBD), Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), and several other cannabinoids against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), human immunodeficiency virus (HIV), and γ-herpes viruses. Mechanisms of action include inhibition of viral cell entry, inhibition of viral proteases, and stimulation of cellular innate immune responses. The anti-inflammatory properties of cannabinoids are also under investigation for mitigating the cytokine storm of COVID-19 and controlling chronic inflammation in people living with HIV. Retrospective clinical studies support antiviral activities of CBD, Δ9-THC, and cannabinoid mixtures as do some prospective clinical trials, but appropriately designed clinical trials of safety and efficacy of antiviral cannabinoids are urgently needed.
,

Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics

The development of long-term symptoms of coronavirus disease 2019 (COVID-19) more than four weeks after primary infection, termed “long COVID” or post-acute sequela of COVID-19 (PASC), can implicate persistent neurological complications in up to one third of patients and present as fatigue, “brain fog”, headaches, cognitive impairment, dysautonomia, neuropsychiatric symptoms, anosmia, hypogeusia, and peripheral neuropathy. Pathogenic mechanisms of these symptoms of long COVID remain largely unclear; however, several hypotheses implicate both nervous system and systemic pathogenic mechanisms such as SARS-CoV2 viral persistence and neuroinvasion, abnormal immunological response, autoimmunity, coagulopathies, and endotheliopathy. Outside of the CNS, SARS-CoV-2 can invade the support and stem cells of the olfactory epithelium leading to persistent alterations to olfactory function. SARS-CoV-2 infection may induce abnormalities in innate and adaptive immunity including monocyte expansion, T-cell exhaustion, and prolonged cytokine release, which may cause neuroinflammatory responses and microglia activation, white matter abnormalities, and microvascular changes. Additionally, microvascular clot formation can occlude capillaries and endotheliopathy, due to SARS-CoV-2 protease activity and complement activation, can contribute to hypoxic neuronal injury and blood–brain barrier dysfunction, respectively. Current therapeutics target pathological mechanisms by employing antivirals, decreasing inflammation, and promoting olfactory epithelium regeneration. Thus, from laboratory evidence and clinical trials in the literature, we sought to synthesize the pathophysiological pathways underlying neurological symptoms of long COVID and potential therapeutics.
,

Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment

Cannabidiol is showing promising results for the treatment of COVID-19, due to its capa- bility of acting on the unleashed cytokine storm, on the proteins necessary for both virus entry and replication and on the neurological consequences of patients who have been infected by the virus. Here, we summarize the latest knowledge regarding the advantages of using cannabinoids in the treatment of COVID-19.

Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis

While cannabis is known to have immunomodulatory properties, the clinical consequences of its use on outcomes in COVID-19 have not been extensively evaluated. We aimed to assess whether cannabis users hospitalized for COVID-19 had improved outcomes compared to non-users.
,

Cannabinoids as Emergent Therapy Against COVID-19

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory distress syndrome coronavirus 2(SARS-Cov-2), was identified for the first time in late 2019 in China, resulting in a global pandemic of massiveimpact. Despite a fast development and implementation of vaccination strategies, and the scouting of severalpharmacological treatments, alternative effective treatments are still needed. In this regard, cannabinoids repre-sent a promising approach because they have been proven to exhibit several immunomodulatory, anti-inflammatory, and antiviral properties in COVID-19 disease models and related pathological conditions. Thismini-review aims at providing a practical brief overview of the potential applications of cannabinoids so far iden-tified for the treatment and prevention of COVID-19, finally considering key aspects related to their technologicaland clinical implementation.
,

Synergy with Cannabis and Other Herbs: Thinking Beyond Plant Constituents

Explore the different types of plant synergy, herbs that may combine well with cannabis, and the healing properties of botanicals that science will never be able to fully explain.
21 years

As an organization

38 States

Members practice in

24 Countries

Our members represent

737 Articles

in the Research Library

Membership & Online Learning

Membership information

Diversity within the SCC is critical to our success and ability to educate each other. Healthcare professionals and allies are welcome to join, including (but not limited to): physicians, nurses, pharmacists, caregivers, veterinarians, herbalists, physical therapists, researchers, and patients.

Video Library

View our robust collection of presentations by leading international experts sharing cannabis science and medical applications. There are various free options available to everyone. Full videos of quarterly meetings and other exclusive content is viewable in the Members Portal.

O’Shaughnessy’s Journal

SCC Founder Tod Mikuriya, MD was a physician, researcher, and creator of a new “Cannabis Clinician” specialty. Tod envisioned a journal where clinicians monitoring patients’ cannabis use could share observations. O’Shaughnessy’s continues to this day.

Global Impact

Affiliates & Allies